Can I get it?
Not for this use. Phentermine has no EU authorisation for it, so it cannot be prescribed or dispensed here for that purpose.
Why buying it online is risky
Phentermine · Tallinn
Phentermine in Tallinn: what you should know.
NOT AVAILABLE IN THE EUPhentermine has no EU marketing authorisation for this use.
We don't prescribe it today, but our doctors can review your case and propose an equivalent weight management treatment with EU approval and clinical evidence.
€25/month (billed €25 every 28 days)Full refund if a review is not approved
IN PLAIN TERMS
What Phentermine is, and how to get treatment
Phentermine is an old appetite-suppressant tablet, related to amphetamine, that is widely prescribed in the United States for short-term weight loss. It is a different situation in Europe. European regulators reviewed this whole class of appetite suppressants in 1999, decided they had not been shown to work over the long term, and the European Commission ordered countries to withdraw them in March 2000. The EU courts later annulled those decisions on a technical point about the Commission's powers, but the products did not return to the market. Phentermine on its own is not authorised as a weight-loss medicine in the European Union today, so an EU doctor cannot prescribe it and an EU pharmacy cannot dispense it. Websites selling phentermine to EU addresses are operating outside EU medicines law, and what arrives in the post has not been checked by any European regulator.
Phentermine has no EU marketing authorisation for this use. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.
What can I take instead?
Semaglutide is approved in the EU, has published peer-reviewed trial results, and can be prescribed today if a doctor decides it suits you.
Read about SemaglutideWhat do the studies show?
Every trial behind Phentermine is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Can I get Phentermine in Tallin?
Not through Hi-Doctor. Hi-Doctor does not prescribe Phentermine. People in Tallin, Estonia, can request an online consultation for Weight loss with a licensed EU doctor, who may recommend an available option when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in Estonia, who dispenses the locally marketed equivalent with the prescribed active ingredient.
Availability
Hi-Doctor does not prescribe Phentermine. The links below show options in Weight loss that our doctors can assess.
- Country
- Estonia
- Language of service
- Spanish and English
- Prescription turnaround
- In less than 4 hours on average, only if the doctor approves
- Honoured locally
- PDF honoured locally for the prescribed active ingredient
How the EU prescription works where you are: In Estonia, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent with the prescribed active ingredient.
TREATMENT OPTIONS
Available medical weight-management options
A licensed doctor decides case by case. We never prescribe without evaluation.
Rx · GLP-1
Prescription only
Semaglutide (Wegovy / Ozempic)
Weekly GLP-1 receptor agonist. A doctor may prescribe it if your BMI and history match the indications. Requires follow-up.
Weekly injection pen
€25/month
Rx · GLP-1 / GIP
Prescription only
Tirzepatide (Mounjaro)
Dual GLP-1/GIP agonist. Assessed by the doctor based on comorbidities and the patient's BMI.
Weekly injection pen
€25/month
Rx · GLP-1
Prescription only
Liraglutide (Saxenda)
Daily GLP-1 agonist. Indicated in selected patients with elevated BMI after medical evaluation.
Daily injection pen
€25/month
Rx · lipase inhibitor
Prescription only
Orlistat 120mg
Fat-absorption inhibitor. A non-GLP-1 alternative a doctor may consider based on your history.
Capsules
€25/month
Rx · oral GLP-1
Prescription only
Rybelsus (oral semaglutide)
A once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.
Daily tablets
€25/month
You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.
WHAT IT COSTS
One plan, reviewed by a doctor.
Weight loss
ONGOING PLAN
€25/month
Billed €25 every 28 days · cancel anytime
28-day treatment cycle
For ongoing treatment and doctor-reviewed renewals.
Renewals reviewed by your doctor
Start consultation
Full refund if a review is not approved
WHAT'S INCLUDED
- First consultation included
- Renewals reviewed by your doctor
- Ongoing care with your doctor
- Cancel anytime
Full refund if a review is not approved
If a review is not approved, we refund that period's €25 fee and cancel the plan.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
VERIFIED EVIDENCE
Phentermine: evidence and regulatory guide.
WHAT IT IS
How it works
An appetite suppressant chemically related to amphetamine that raises the level of noradrenaline in the brain, which reduces feelings of hunger.
- Noradrenaline release
- Dopamine release
DEVELOPMENT STAGE
Not marketed in the EU
Trial register1 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| EQUATENCT00563368 | Adults with obesity (BMI 30-45), randomised across placebo, phentermine alone, topiramate alone and the two in combination | 756 | Read out | 2013-11-01 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Aronne LJ, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults (EQUATE). Obesity (Silver Spring). 2013. doi:10.1002/oby.20584 (PMID 24136928)| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| Phentermine 7.5 mg daily (alone) | 43.3% of participants lost at least 5% of body weight | 28 |
| Phentermine 15 mg daily (alone) | 46.2% of participants lost at least 5% of body weight | 28 |
| Placebo | 15.5% of participants lost at least 5% of body weight | 28 |
EQUATE lasted only 28 weeks and was designed to test a phentermine/topiramate combination — the phentermine-only groups were comparison arms. There is no modern long-term trial of phentermine on its own, and EU regulators concluded in 1999 that this class of appetite suppressant had not shown long-term efficacy in obesity.
Sources
Last reviewed 2026-07-27
- EUR-Lex — Commission Decision C(2000) 452 of 9 March 2000 withdrawing marketing authorisations for phentermine-containing medicines (as recounted in Case C-39/03 P)
- EUR-Lex — Artegodan and Others v Commission, Joined Cases T-74/00 and others (annulment of the 2000 withdrawal decisions)
- EMA — Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine/topiramate)
- Swedish Medical Products Agency — Qsiva Public Assessment Report (phentermine pharmacology and abuse potential)
- Obesity — EQUATE trial (Aronne 2013)
- ClinicalTrials.gov · NCT00563368
NAMED SAFETY SIGNALS
What has been reported with Phentermine.
Increased heart rate
Phentermine is known to increase heart rate; the EMA's committee cited this, and the unclear long-term effects on the heart and blood vessels, as a reason for refusing the EU-wide phentermine/topiramate application.
Potential for misuse
The Swedish Medical Products Agency assessment notes that phentermine's structural, pharmacological and neurochemical profile is similar to amphetamine and that abuse potential has been shown in animal studies, so a warning is carried in the product information.
Historical concerns for this drug class
Appetite suppressants as a class have been associated with pulmonary hypertension and heart valve disease; the Swedish assessment records the applicant's position that there is no evidence of these specifically with phentermine alone.
Judged not to have shown long-term benefit in the EU
In 1999 the EU's Committee for Proprietary Medicinal Products concluded phentermine and related appetite suppressants did not meet the standard for long-term efficacy in obesity, and the European Commission ordered national marketing authorisations withdrawn on 9 March 2000.
UNAPPROVED PRODUCTS ONLINE
Why buying Phentermine online is not a shortcut.
No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.
Check the EU common logo
A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.
How the EU common logo worksFREQUENTLY ASKED QUESTIONS
Questions about Phentermine.
OTHER WEIGHT LOSS TREATMENTS